Invention Summary:

Chlamydial infection is caused by Chlamydia trachomatis bacterium and is one of the most common sexually transmitted infections worldwide. As per U.S. Centers for Disease Control and Prevention estimates, there are 4 million new cases of Chlamydial infections each year. Chlamydial infection often results in abnormal discharge from female and male sexual organs and pain while urinating. If left untreated, the infection may spread to other organs of the body causing pelvic inflammatory disease (PID) in women and epidydimitis in men, inflamed rectum and inflammation of the eye. Approximately 600 million people worldwide suffer C. trachomatis eye infections and 20 million are blinded as a result of the infection. Current treatment methods include the use of antibiotics such as azithromycin, doxycycline, erythromycin, or ofloxacin. The use of prescription antiobiotics poses the risk of developing antibiotic resistance and disruption of normal microbial floras. Thus, there is a long felt medical need for alternative treatment strategies that overcome the aforementioned limitations.

The present technology represents a novel strategy to effectively prevent and eliminate C. trachomatis infection. The current invention disclosed new methods to prevent and treat Chlamydia infection using certain metalloprotease inhibitors. Topical composition containing such metalloprotease inhibitors can be applied to the infected site or a site likely to be infected. Topical composition containing such metalloprotease inhibitors can also be used to coat barrier contraceptive devices for reducing the risk of Chlamydia infection.

Market Applications:

Prevention and treatment of chlamydia infection


  • Non-antibiotic treatment
  • Ready to be applied to the infected sites or sites likely to be infected
  • Specific to Chlamydia infection, normal microbial flora will not be destroyed

Intellectual Property & Development Status:

  • United States patent number US 7,863,335 B2 granted on January 4, 2011
  • Published PCT application: PCT/US2005/026333
Rutgers ID: S03-38
Life Sciences
Yong Zhang
Licensing Manager
Huizhou Fan
Infectious Disease/Immunology
Small Molecules